Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $15.49 in the last session, up 3.47% from day before closing price of $14.97. In other words, the price has increased by $3.47 from its previous closing price. On the day, 0.67 million shares were traded. SYRE stock price reached its highest trading level at $15.95 during the session, while it also had its lowest trading level at $14.49.
Ratios:
We take a closer look at SYRE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.06 and its Current Ratio is at 8.06. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 08, 2025, initiated with a Outperform rating and assigned the stock a target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.
On September 04, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $45.Wedbush initiated its Outperform rating on September 04, 2024, with a $45 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 06 ’24 when Albers Jeffrey W. sold 6,700 shares for $36.76 per share. The transaction valued at 246,313 led to the insider holds 27,360 shares of the business.
Albers Jeffrey W. sold 300 shares of SYRE for $10,929 on Oct 25 ’24. The Director now owns 34,060 shares after completing the transaction at $36.43 per share. On Oct 25 ’24, another insider, SESSIONS, LLC, who serves as the Director of the company, bought 7,000 shares for $33.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 934877248 and an Enterprise Value of 494492800.
Stock Price History:
The Beta on a monthly basis for SYRE is 2.69, which has changed by -0.39868015 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.26, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 1.54%, while the 200-Day Moving Average is calculated to be -30.15%.
Shares Statistics:
According to the various share statistics, SYRE traded on average about 650.87K shares per day over the past 3-months and 819430 shares per day over the past 10 days. A total of 60.28M shares are outstanding, with a floating share count of 51.32M. Insiders hold about 14.97% of the company’s shares, while institutions hold 99.28% stake in the company. Shares short for SYRE as of 1749772800 were 12592074 with a Short Ratio of 19.35, compared to 1747267200 on 12296733. Therefore, it implies a Short% of Shares Outstanding of 12592074 and a Short% of Float of 26.790002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
